A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 13, 2013

Bee Venom: The Next Anti-HIV Agent? A Proof-of-Concept Study Says Yes

Nanoparticles filled with a toxin called melittin that’s found in bee venom can destroy HIV and have a benign effect on surrounding cells, Medical News Today reports. Publishing the results of their proof-of-concept study in the March 2013 issue of Antiviral Therapy, researchers from Washington University School of Medicine in St. Louis added “protective bumpers” to the surface of the melittin-filled nanoparticles. These bumpers prevented normal cells, which are most often larger, from coming into contact with the melittin-coated surface. HIV, on the other hand, would fit in between these bumpers and the melittin would fuse with its viral envelope, rupture the envelope and tear it from the virus—effectively killing the virus.

This line of attack is different from the one taken by antiretrovirals (ARVs), which arrest different phases in the virus’s lifecycle instead of killing it entirely. Such a novel approach would be able to keep HIV from beginning an infection of a cell in the first place. Researchers hope melittin may be used as a vaginal microbicide or as a salvage therapy for people with HIV who have failed numerous classes of ARVs. In addition, because melittin attacks cells indiscriminately, it may prove an effective therapy for hepatitis B and C viruses (HBV/HCV) and other pathogens that count on a viral envelope for survival.

To read the study abstract, click here.

To read the Medical News Today report, click here. 

Search: nanoparticles, toxin, bee venom, melittin, Medical News Today, Antiviral Therapy, Washington University School of Medicine, protective bumpers, HIV, hepatitis C, hepatitis B.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (4 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.